An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease

Biomaterials

Volumn 48, Issue , 2015, Pages 26-36

  Huang, Zhen ^a   Gan, Jingjing ^a   Jia, Lixin ^a   Guo, Guangxing ^a   Wang, Chunming ^a,b   Zang, Yuhui ^a   Ding, Zhi ^a   Chen, Jiangning ^a   Zhang, Junfeng ^a   Dong, Lei ^a  

^a NANJING UNIVERSITY   (China)

^b UNIVERSITY OF MACAU   (Macao)

Author keywords

Antisense oligonucleotide; Colonic macrophages; Inflammatory bowel disease; Targeting delivery; TNF

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; CELL DEATH; CONTROLLED DRUG DELIVERY; DISEASES; MACROPHAGES; MAMMALS; OLIGONUCLEOTIDES; SODIUM SULFATE; SULFUR COMPOUNDS; VEHICLES;

ANTISENSE OLIGONUCLEOTIDES; DRUG DELIVERY SYSTEM; INFLAMMATORY BOWEL DISEASE; ORAL ADMINISTRATION; SPONTANEOUS RELEASE; SWELLING PROPERTIES; TARGETING DELIVERIES; TUMOR NECROSIS FACTOR ALPHA;

TARGETED DRUG DELIVERY;

ANTISENSE OLIGONUCLEOTIDE; CATIONIC KONJAC GLUCOMANNAN; DEXTRAN SULFATE; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; MANNAN; MICROSPHERE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; NUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISENSE THERAPY; ARTICLE; CELL VIABILITY; COLONIC MACROPHAGE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; EXPERIMENTAL COLITIS; FEMALE; GENETIC TRANSFECTION; IN VITRO GENE TRANSFER; IN VITRO STUDY; INFLAMMATORY BOWEL DISEASE; LAMINA PROPRIA; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; BIOSYNTHESIS; CELL LINE; COLON; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; INFRARED SPECTROSCOPY; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY;

MUS;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE; COLON; IN VITRO TECHNIQUES; INFLAMMATORY BOWEL DISEASES; MACROPHAGES; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSPHERES; NUCLEOTIDES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924956742     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.01.013     Document Type: Article

References (28)

1. Abraham C., Cho J.H. Inflammatory bowel disease. NEngl J Med 2009, 361:2066-2078.
2. Heinsbroek S.E., Gordon S. The role of macrophages in inflammatory bowel diseases. Expert Rev Mol Med 2009, 11:e14.
3. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. Ashort-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. NEngl J Med 1997, 337:1029-1035.
4. Ben-Horin S., Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014, 11:243-255.
5. Travassos W.J., Cheifetz A.S. Infliximab: use in inflammatory bowel disease. Curr Treat Options Gastroenterol 2005, 8:187-196.
6. Ricart E., Ordas I., Panes J. Anti-TNF antibody therapy in Crohn's disease: the risk of a switch. Gut 2012, 61:169-170.
7. Schneeweiss S., Korzenik J., Solomon D.H., Canning C., Lee J., Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009, 30:253-264.
8. Linehan S.A., Martinez-Pomares L., Gordon S. Mannose receptor and scavenger receptor: two macrophage pattern recognition receptors with diverse functions in tissue homeostasis and host defense. Adv Exp Med Biol 2000, 479:1-14.
9. Keithley J., Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med 2005, 11:30-34.
10. Huang Z., Yang Y., Jiang Y., Shao J., Sun X., Chen J., et al. Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers. Biomaterials 2013, 34:746-755.
11. Huang Z., Zhang Z., Zha Y., Liu J., Jiang Y., Yang Y., et al. The effect of targeted delivery of anti-TNF-alpha oligonucleotide into CD169+ macrophages on disease progression in lupus-prone MRL/lpr mice. Biomaterials 2012, 33:7605-7612.
12. Chua M., Chan K., Hocking T.J., Williams P.A., Perry C.J., Baldwin T.C. Methodologies for the extraction and analysis of konjac glucomannan from corms of Amorphophallus konjac K. Koch. Carbohydr Polym 2012, 87:2202-2210.
13. Wang C., Gong Y., Lin Y., Shen J., Wang D.A. Anovel gellan gel-based microcarrier for anchorage-dependent cell delivery. Acta Biomater 2008, 4:1226-1234.
14. Huang Z., Shi T., Zhou Q., Shi S., Zhao R., Shi H., et al. miR-141 Regulates colonic leukocytic trafficking by targeting CXCL12beta during murine colitis and human Crohn's disease. Gut 2014, 63:1247-1257.
15. Huang Z., Zhang Z., Jiang Y., Zhang D., Chen J., Dong L., et al. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. JControl Release 2012, 158:286-292.
16. Stallmach A., Hagel S., Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 2010, 24:167-182.
17. Zuo L., Huang Z., Dong L., Xu L., Zhu Y., Zeng K., et al. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut 2010, 59:470-479.
18. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010, 9:615-627.
19. Kriegel C., Amiji M. Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. JControl Release 2011, 150:77-86.
20. Wilson D.S., Dalmasso G., Wang L., Sitaraman S.V., Merlin D., Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 2010, 9:923-928.
21. Kriegel C., Attarwala H., Amiji M. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Adv Drug Deliv Rev 2013, 65:891-901.
22. Laroui H., Viennois E., Xiao B., Canup B.S., Geem D., Denning T.L., et al. Fab'-bearing siRNA TNFalpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. JControl Release 2014, 186:41-53.
23. Xiao B., Laroui H., Ayyadurai S., Viennois E., Charania M.A., Zhang Y., et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy. Biomaterials 2013, 34:7471-7482.
24. Brown G.D., Taylor P.R., Reid D.M., Willment J.A., Williams D.L., Martinez-Pomares L., et al. Dectin-1 is a major beta-glucan receptor on macrophages. JExp Med 2002, 196:407-412.
25. Roy K., Mao H.Q., Huang S.K., Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999, 5:387-391.
26. Bhavsar M.D., Amiji M.M. Gastrointestinal distribution and invivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). JControl Release 2007, 119:339-348.
27. Sood N., Baker W.L., Coleman C.I. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr 2008, 88:1167-1175.
28. Albrecht S., van Muiswinkel G.C., Xu J., Schols H.A., Voragen A.G., Gruppen H. Enzymatic production and characterization of konjac glucomannan oligosaccharides. JAgric Food Chem 2011, 59:12658-12666.